A clinical trial (BATURA) has shown the efficacy of AstraZenaca’s AIRSUPRA (albuterol/budesonide) in reducing the risk of severe asthma exacerbations. AIRSUPRA, an inhaled anti-inflammatory rescue medication, was tested against albuterol alone in patients with intermittent or mild persistent asthma, including those taking maintenance therapy.
The trial met its primary endpoint, demonstrating a statistically significant reduction in the risk of severe exacerbations when AIRSUPRA was used as a rescue medication. The medication was effective in reducing the need for systemic corticosteroids.
The safety profile of AIRSUPRA was consistent with its established profile, and no new safety concerns were reported. The efficacy and safety data from the BATURA trial will be presented at an upcoming medical conference.
AIRSUPRA is the first anti-inflammatory rescue medication approved for treating asthma in adults in the US. It provides a dual-action approach by treating both and inflammation, reducing the risk of severe exacerbations and the need for additional treatments.
AIRSUPRA is currently being studied in adolescents with asthma and patients in China. Its development is a collaboration between AstraZeneca and Avillion.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
